The oncology proteomics market is set to grow from 2034, driven by rising cancer prevalence, biomarker research, and demand for targeted therapies. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Oncology Proteomics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Oncology Proteomics Market, by Component
8.1.1. Instruments
8.1.1.1. Market Revenue and Forecast
8.1.2. Reagents & Consumables
8.1.2.1. Market Revenue and Forecast
8.1.3. Software & Services
8.1.3.1. Market Revenue and Forecast
9.1. Oncology Proteomics Market, by Application
9.1.1. Cancer Biomarker Discovery & Validation
9.1.1.1. Market Revenue and Forecast
9.1.2. Oncology Drug Discovery & Development
9.1.2.1. Market Revenue and Forecast
9.1.3. Immuno-Oncology & Proteomics
9.1.3.1. Market Revenue and Forecast
10.1. Oncology Proteomics Market, by Technology
10.1.1. Mass Spectrometry-Based Oncology Proteomics
10.1.1.1. Market Revenue and Forecast
10.1.2. Chromatography-Based Proteomics for Cancer Drug Analysis
10.1.2.1. Market Revenue and Forecast
10.1.3. AI-Driven Proteomics for Cancer Drug Targeting
10.1.3.1. Market Revenue and Forecast
10.1.4. Single-Cell Proteomics for Tumor Heterogeneity Analysis
10.1.4.1. Market Revenue and Forecast
10.1.5. Protein Microarrays for High-Throughput Cancer Biomarker Screening
10.1.5.1. Market Revenue and Forecast
10.1.6. Spatial Proteomics for Tumor Microenvironment Analysis
10.1.6.1. Market Revenue and Forecast
10.1.7. Multiplexed Imaging-Based Spatial Proteomics for Cancer Research
10.1.7.1. Market Revenue and Forecast
10.1.8. Spatially-driven Biomarker Discovery for Immuno-Oncology
10.1.8.1. Market Revenue and Forecast
11.1. Oncology Proteomics Market, by End-Use
11.1.1. Pharmaceutical & Biotechnology Companies Focused on Oncology
11.1.1.1. Market Revenue and Forecast
11.1.2. Oncology Research Institutions & Hospitals
11.1.2.1. Market Revenue and Forecast
11.1.3. Contract Research Organizations (CROs) Specializing in Cancer Proteomics
11.1.3.1. Market Revenue and Forecast
11.1.4. Oncology-Specific Clinical Diagnostic Laboratory
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Component
12.1.2. Market Revenue and Forecast, by Application
12.1.3. Market Revenue and Forecast, by Technology
12.1.4. Market Revenue and Forecast, by End-Use
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Component
12.1.5.2. Market Revenue and Forecast, by Application
12.1.5.3. Market Revenue and Forecast, by Technology
12.1.5.4. Market Revenue and Forecast, by End-Use
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Component
12.1.6.2. Market Revenue and Forecast, by Application
12.1.6.3. Market Revenue and Forecast, by Technology
12.1.6.4. Market Revenue and Forecast, by End-Use
12.2. Europe
12.2.1. Market Revenue and Forecast, by Component
12.2.2. Market Revenue and Forecast, by Application
12.2.3. Market Revenue and Forecast, by Technology
12.2.4. Market Revenue and Forecast, by End-Use
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Component
12.2.5.2. Market Revenue and Forecast, by Application
12.2.5.3. Market Revenue and Forecast, by Technology
12.2.5.4. Market Revenue and Forecast, by End-Use
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Component
12.2.6.2. Market Revenue and Forecast, by Application
12.2.6.3. Market Revenue and Forecast, by Technology
12.2.6.4. Market Revenue and Forecast, by End-Use
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Component
12.2.7.2. Market Revenue and Forecast, by Application
12.2.7.3. Market Revenue and Forecast, by Technology
12.2.7.4. Market Revenue and Forecast, by End-Use
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Component
12.2.8.2. Market Revenue and Forecast, by Application
12.2.8.3. Market Revenue and Forecast, by Technology
12.2.8.4. Market Revenue and Forecast, by End-Use
12.3. APAC
12.3.1. Market Revenue and Forecast, by Component
12.3.2. Market Revenue and Forecast, by Application
12.3.3. Market Revenue and Forecast, by Technology
12.3.4. Market Revenue and Forecast, by End-Use
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Component
12.3.5.2. Market Revenue and Forecast, by Application
12.3.5.3. Market Revenue and Forecast, by Technology
12.3.5.4. Market Revenue and Forecast, by End-Use
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Component
12.3.6.2. Market Revenue and Forecast, by Application
12.3.6.3. Market Revenue and Forecast, by Technology
12.3.6.4. Market Revenue and Forecast, by End-Use
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Component
12.3.7.2. Market Revenue and Forecast, by Application
12.3.7.3. Market Revenue and Forecast, by Technology
12.3.7.4. Market Revenue and Forecast, by End-Use
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Component
12.3.8.2. Market Revenue and Forecast, by Application
12.3.8.3. Market Revenue and Forecast, by Technology
12.3.8.4. Market Revenue and Forecast, by End-Use
12.4. MEA
12.4.1. Market Revenue and Forecast, by Component
12.4.2. Market Revenue and Forecast, by Application
12.4.3. Market Revenue and Forecast, by Technology
12.4.4. Market Revenue and Forecast, by End-Use
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Component
12.4.5.2. Market Revenue and Forecast, by Application
12.4.5.3. Market Revenue and Forecast, by Technology
12.4.5.4. Market Revenue and Forecast, by End-Use
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Component
12.4.6.2. Market Revenue and Forecast, by Application
12.4.6.3. Market Revenue and Forecast, by Technology
12.4.6.4. Market Revenue and Forecast, by End-Use
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Component
12.4.7.2. Market Revenue and Forecast, by Application
12.4.7.3. Market Revenue and Forecast, by Technology
12.4.7.4. Market Revenue and Forecast, by End-Use
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Component
12.4.8.2. Market Revenue and Forecast, by Application
12.4.8.3. Market Revenue and Forecast, by Technology
12.4.8.4. Market Revenue and Forecast, by End-Use
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Component
12.5.2. Market Revenue and Forecast, by Application
12.5.3. Market Revenue and Forecast, by Technology
12.5.4. Market Revenue and Forecast, by End-Use
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Component
12.5.5.2. Market Revenue and Forecast, by Application
12.5.5.3. Market Revenue and Forecast, by Technology
12.5.5.4. Market Revenue and Forecast, by End-Use
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Component
12.5.6.2. Market Revenue and Forecast, by Application
12.5.6.3. Market Revenue and Forecast, by Technology
12.5.6.4. Market Revenue and Forecast, by End-Use
13.1. Illumina, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Agilent Technologies, Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Bio-Rad Laboratories, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Thermo Fisher Scientific, Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Bruker Corporation
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. F. Hoffmann-La Roche Ltd.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Waters Corporation
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Merck KGaA
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Danaher
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Standard BioTools Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description